KYTX: KYVERNA THERAPEUTICS INC Stocks News on November 9, 2024

Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors

KYTX

PR Newswire

19 days ago

Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors

KYTX

Insider Monkey

20 days ago

Kyverna Therapeutics (KYTX): Leading Nano Cap with Promising CAR T-Cell Therapy

JPMorgan Chase & Co's Strategic Acquisition in Kyverna Therapeutics Inc

KYTX

GuruFocus.com

a month ago

JPMorgan Chase & Co's Strategic Acquisition in Kyverna Therapeutics Inc

KYTX

MT Newswires

a month ago

UBS Initiates Kyverna Therapeutics at Buy With $13 Price Target

Kyverna Therapeutics Presents Patient Data Reinforcing Potential of KYV-101 for Treatment of Neuroinflammatory Diseases in Symposium at ECTRIMS 2024

KYTX

PR Newswire

2 months ago

Kyverna Therapeutics Presents Patient Data Reinforcing Potential of KYV-101 for Treatment of Neuroinflammatory Diseases in Symposium at ECTRIMS 2024

KYTX

MT Newswires

2 months ago

Kyverna Therapeutics Names Warner Biddle CEO

Kyverna Therapeutics Announces Leadership Update

KYTX

PR Newswire

2 months ago

Kyverna Therapeutics Announces Leadership Update

Kyverna swaps CEOs, leaning on Kite veterans to lead ‘next chapter’

KYTX

BioPharma Dive

2 months ago

Kyverna swaps CEOs, leaning on Kite veterans to lead ‘next chapter’

Kyverna Therapeutics to Participate in Upcoming September Investor Conferences

KYTX

PR Newswire

3 months ago

Kyverna Therapeutics to Participate in Upcoming September Investor Conferences

KYTX

MT Newswires

3 months ago

Kyverna Therapeutics Says FDA Grants Regenerative Medicine Advanced Therapy Designation to Autoimmune Disorder Drug

Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

KYTX

PR Newswire

3 months ago

Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Kyverna Therapeutics Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Progressive Myasthenia Gravis

KYTX

PR Newswire

3 months ago

Kyverna Therapeutics Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Progressive Myasthenia Gravis

KYTX

Simply Wall St.

3 months ago

We Think Kyverna Therapeutics (NASDAQ:KYTX) Can Afford To Drive Business Growth

Biotech Stock Roundup: LXRX Up on Regulatory Update, SAVA, LXEO Down on Updates

KYTX

Zacks

4 months ago

Biotech Stock Roundup: LXRX Up on Regulatory Update, SAVA, LXEO Down on Updates

Kyverna wins RMAT designation for stiff-person syndrome for cell therapy candidate

KYTX

Pharmaceutical Technology

4 months ago

Kyverna wins RMAT designation for stiff-person syndrome for cell therapy candidate

KYTX

Zacks

4 months ago

Kyverna (KYTX) Gets RMAT Designation for CAR T-Cell Product

KYTX

MT Newswires

4 months ago

Kyverna Therapeutics Gets FDA RMAT Designation for Stiff-Person Syndrome Treatment; Shares Rise After Hours

$Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome$

KYTX

PR Newswire

4 months ago

Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome

$Kyverna's KYV-101 Receives U.S. FDA IND Clearance for Treatment of Patients With Treatment-Refractory Stiff-Person Syndrome in the KYSA-8 Phase 2 Trial$

KYTX

PR Newswire

5 months ago

Kyverna's KYV-101 Receives U.S. FDA IND Clearance for Treatment of Patients With Treatment-Refractory Stiff-Person Syndrome in the KYSA-8 Phase 2 Trial

First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patient With Severe Stiff-Person Syndrome Published in Proceedings of the National Academy of Sciences (PNAS)

KYTX

PR Newswire

5 months ago

First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patient With Severe Stiff-Person Syndrome Published in Proceedings of the National Academy of Sciences (PNAS)

Kyverna Therapeutics and National Institutes of Health Co-Author Seminal Review on Cell Therapy for Autoimmunity in Nature Reviews Immunology

KYTX

PR Newswire

5 months ago

Kyverna Therapeutics and National Institutes of Health Co-Author Seminal Review on Cell Therapy for Autoimmunity in Nature Reviews Immunology

Kyverna Therapeutics to Present Data on 50 Patient Experience at Symposium at EULAR 2024

KYTX

PR Newswire

5 months ago

Kyverna Therapeutics to Present Data on 50 Patient Experience at Symposium at EULAR 2024

Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

KYTX

PR Newswire

6 months ago

Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases

KYTX

PR Newswire

7 months ago

Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases

First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med

KYTX

PR Newswire

7 months ago

First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med

Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results

KYTX

PR Newswire

7 months ago

Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results

Why That Hot Biotech IPO Could Be a Winner

KYTX

The Wall Street Journal

8 months ago

Why That Hot Biotech IPO Could Be a Winner

Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis

KYTX

PR Newswire

8 months ago

Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis

How Kyverna is positioned for success on autoimmune therapy: CEO

KYTX

Yahoo Finance Video

8 months ago

How Kyverna is positioned for success on autoimmune therapy: CEO

Kyverna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

KYTX

PR Newswire

9 months ago

Kyverna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering

KYTX

PR Newswire

9 months ago

Latest KYVERNA THERAPEUTICS INC (KYTX) News on November 9, 2024

Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors

Kyverna Therapeutics (KYTX): Leading Nano Cap with Promising CAR T-Cell Therapy

JPMorgan Chase & Co's Strategic Acquisition in Kyverna Therapeutics Inc

UBS Initiates Kyverna Therapeutics at Buy With $13 Price Target

Kyverna Therapeutics Presents Patient Data Reinforcing Potential of KYV-101 for Treatment of Neuroinflammatory Diseases in Symposium at ECTRIMS 2024

Kyverna Therapeutics Names Warner Biddle CEO

Kyverna Therapeutics Announces Leadership Update

Kyverna swaps CEOs, leaning on Kite veterans to lead ‘next chapter’

Kyverna Therapeutics to Participate in Upcoming September Investor Conferences

Kyverna Therapeutics Says FDA Grants Regenerative Medicine Advanced Therapy Designation to Autoimmune Disorder Drug

Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Kyverna Therapeutics Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Progressive Myasthenia Gravis

We Think Kyverna Therapeutics (NASDAQ:KYTX) Can Afford To Drive Business Growth

Biotech Stock Roundup: LXRX Up on Regulatory Update, SAVA, LXEO Down on Updates

Kyverna wins RMAT designation for stiff-person syndrome for cell therapy candidate

Kyverna (KYTX) Gets RMAT Designation for CAR T-Cell Product

Kyverna Therapeutics Gets FDA RMAT Designation for Stiff-Person Syndrome Treatment; Shares Rise After Hours

Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome

Kyverna's KYV-101 Receives U.S. FDA IND Clearance for Treatment of Patients With Treatment-Refractory Stiff-Person Syndrome in the KYSA-8 Phase 2 Trial

First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patient With Severe Stiff-Person Syndrome Published in Proceedings of the National Academy of Sciences (PNAS)

Kyverna Therapeutics and National Institutes of Health Co-Author Seminal Review on Cell Therapy for Autoimmunity in Nature Reviews Immunology

Kyverna Therapeutics to Present Data on 50 Patient Experience at Symposium at EULAR 2024

Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases

First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med

Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results

Why That Hot Biotech IPO Could Be a Winner

Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis

How Kyverna is positioned for success on autoimmune therapy: CEO

Kyverna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering

Share on Social Networks: